시장보고서
상품코드
1987975

뼈핀 시장 : 제품 유형별, 재료별, 용도별, 최종 사용자별, 판매 채널별 - 시장 예측(2026-2032년)

Bone Pins Market by Product Type, Material, Application, End User, Sales Channel - Global Forecast 2026-2032

발행일: | 리서치사: 구분자 360iResearch | 페이지 정보: 영문 198 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

뼈핀 시장은 2025년에 1억 8,739만 달러로 평가되었고, 2026년에는 1억 9,945만 달러로 성장할 전망이며, CAGR 6.51%로 성장을 지속하여, 2032년까지 2억 9,156만 달러에 이를 것으로 예측됩니다.

주요 시장 통계
기준 연도 : 2025년 1억 8,739만 달러
추정 연도 : 2026년 1억 9,945만 달러
예측 연도 : 2032년 2억 9,156만 달러
CAGR(%) 6.51%

현대 임플란트 선택의 기초, 뼈핀의 임상적 중요성, 제조 기술의 발전, 이해관계자의 우선순위에 관한 종합적인 프레임워크

뼈핀은 현대 정형외과 및 치과 의료에서 매우 중요한 역할을 하고 있으며, 광범위한 근골격계 손상 후 해부학적 연속성을 회복하고 기능적 회복을 가능하게 하는 필수적인 기계적 인터페이스 역할을 하고 있습니다. 임상의는 생역학적 강도, 내식성, 생체 적합성, 장기적인 환자 결과의 균형을 맞추기 위해 다양한 재료와 디자인 중에서 선택합니다. 이와 함께 제조업체들은 합병증 감소, 뼈와의 결합력 향상, 최소 침습적 접근을 목표로 재료과학의 발전과 제조 기술의 정교화를 추구하고 있습니다. 본 논문은 뼈핀을 임플란트 기기라는 더 큰 생태계에 위치시키고, 임상적 요구사항, 규제 당국의 기대, 공급망 역학의 상호 작용에 초점을 맞추었습니다.

재료 혁신, 최소침습 기술, 진화하는 조달 프레임워크가 제품 개발 및 임상 도입 동향을 어떻게 변화시키고 있는가?

뼈핀 시장 상황은 기술적, 임상적, 운영상의 변화가 교차하면서 급속한 변화를 겪고 있습니다. 재료의 혁신이 최전선에 있으며, 새로운 생분해성 폴리머와 마그네슘 합금은 이차적 제거 절차의 필요성을 줄이는 것을 우선시하는 외과 의사의 치료 방침을 바꾸고 있습니다. 동시에 적층제조(적층제조)와 정밀 가공을 통해 공차를 엄격하게 하고, 표면 마감을 개선하고, 1차 안정성을 높이면서 연부조직에 대한 자극을 줄이는 복잡한 형태를 구현할 수 있게 되었습니다. 이러한 기술적 발전은 임플란트 성능에 직접적인 영향을 미치며, 특정 핀 유형이 임상적으로 적응증이 되는 사례의 범위를 넓히고 있습니다.

2025년 관세 환경은 뼈핀 공급망 전반에 걸쳐 전략적 조달, 니어쇼어링, 재고 탄력성 전략에 대한 압박을 가하고 있습니다.

2025년 미국의 관세 정책 전환은 의료기기 제조업체공급망 계획과 조달 전략에 새로운 고려 사항을 가져왔으며, 특히 뼈핀 관련 생태계에 영향을 미쳤습니다. 그동안 국경을 초월한 제조 및 부품 조달에 의존하던 기업들은 비용 구조와 납기를 재조정해야 했고, 니어쇼어링과 공급업체 기반의 다변화가 촉진되었습니다. 이러한 정책 환경은 병원, 외래 진료센터, 정형외과 클리닉에 안정적인 공급을 유지하기 위해 강력한 물류 계획과 재고 버퍼의 중요성을 더욱 강조하고 있습니다.

재료 유형, 제품 유형, 임상 용도, 최종 사용자 환경, 상업화 시 판매 채널에 미치는 영향에 대한 정밀한 인사이트 제공

세부적인 세분화 관점을 통해 뼈핀 부문에서 혁신과 상업적 초점이 어디에 집중되어 있는지를 명확히 할 수 있습니다. 재료별로 분석하면, 제품 이해관계자들은 생분해성, 스테인리스 스틸, 티타늄 중에서 선택을 진행하고 있습니다. 생분해성 솔루션 내에서 금속과 폴리머의 접근 방식은 더욱 구분되며, 마그네슘 합금과 같은 금속 기반 생분해성 솔루션은 흡수 동역학 및 기계적 특성에서 폴리글리콜산 및 폴리유산과 같은 폴리머 기반 옵션과 대조됩니다. 이러한 재료의 차이는 환자의 요구(일시적 지지 또는 영구적 고정 여부)와 임플란트의 생체 거동을 일치시킴으로써 임상적 의사결정 과정을 형성하고 있습니다.

미주, 유럽, 중동, 아프리카, 아시아태평양의 임상 도입, 규제 정합성, 유통 전략을 형성하는 지역별 시장 역학

지역별 동향은 뼈핀 시장의 임상 관행, 규제 당국의 기대, 상업적 전략에 중요한 영향을 미치고 있습니다. 북미와 남미에서 임상 도입은 첨단 병원 시스템과 처리 능력과 예측 가능한 치료 결과를 우선시하는 외래 진료 센터의 확장하는 네트워크의 조합에 의해 영향을 받고 있습니다. 이 환경에서는 수술 전후의 워크플로우를 간소화하고 환자 중심의 명확한 이점을 입증하는 장치가 평가됩니다. 이 시장을 겨냥한 제조업체들은 병원 구매 부서의 요구 사항을 충족시키기 위해 엄격한 규제 기준 준수와 신속한 대응이 가능한 상업적 지원 시스템을 우선시하는 경우가 많습니다.

소재 차별화, 임상적 증거, 판매 채널의 진화가 어떻게 리더십과 틈새 기회를 결정하는지 밝혀주는 경쟁 구도 분석

뼈핀 부문의 경쟁 역학은 전통적인 의료기기 제조업체와 틈새 재료 및 임상 용도 분야에 특화된 전문 기업이 혼재되어 있습니다. 주요 기업들은 수술 후 합병증 감소와 보행 시작까지의 기간 단축을 위해 차별화된 소재 개발, 제조 정확도 향상, 멸균 포장 혁신, 임상의사 교육 프로그램 등 서비스 제공 확대에 주력하고 있습니다. 많은 시장 선도기업들은 규제 준수와 지불자와의 소통을 지원하기 위해 전향적 임상 레지스트리와 시판 후 조사를 포함한 증거 창출에 투자하고 있습니다.

제조업체 및 공급업체가 혁신, 지역 내 비즈니스 연속성, 임상 파트너십, 다양한 상업적 모델을 통합하기 위한 실질적인 전략적 우선순위

업계 선두 기업들은 공급의 신뢰성과 임상적 타당성을 확보하는 동시에 혁신을 가속화하기 위해 다각적인 전략을 채택해야 합니다. 첫째, 생분해성 합금과 폴리머 플랫폼을 모두 추진하는 모듈형 R&D 로드맵을 우선시하고, 임상적 증거와 외과 의사의 선호도 변화에 따라 재료를 전환할 수 있도록 제조의 유연성을 유지합니다. 둘째, 국경 간 관세 변동에 대한 영향을 줄이고 병원의 구매 주기에 대한 대응력을 높이기 위해 현지 마무리 및 멸균 능력에 투자해야 합니다. 셋째, 체계적인 교육 프로그램, 실제 데이터(REW) 생성, 레지스트리 참여를 통해 임상의 이해관계자와의 협력을 강화하고, 신뢰를 구축하며, 장기적인 성과를 입증해야 합니다.

임상 문헌, 규제 당국의 검토, 이해관계자 인터뷰를 결합한 투명한 삼각측량 조사 방법을 통해 연구 결과와 실무적 시사점을 검증합니다.

본 조사에서는 체계적 문헌 검토, 규제 당국에 제출한 서류 분석, 주요 이해관계자들과의 대화를 통한 삼각측량 방법을 적용하여 견고하고 검증 가능한 결과를 도출하고자 했습니다. 재료 분류 및 제품 유형별 안전성 및 성능 동향을 평가하기 위해, 심사 완료된 임상 연구 및 의료기기 레지스트리를 면밀히 검토하고, 규제 문서 및 표준을 검토하여 컴플라이언스 추이를 파악했습니다. 또한, 공급업체의 공개 정보, 특허 출원, 제조 공정 설명을 통합하여 기술적 전환점 및 생산상의 제약 사항을 파악했습니다.

뼈핀 부문에서 지속적인 경쟁 우위의 조건에 초점을 맞춘 임상적, 기술적, 운영적 촉진요인 통합

결론적으로, 뼈핀은 여전히 정형외과와 치과 의료의 기초 요소이지만, 재료의 혁신, 임상 채널의 변화, 조달 행동의 진화로 인해 그 상황이 재구성되고 있습니다. 생분해성 재료와 첨단 합금은 임플란트의 영구성과 수술 후 관리에 대한 판단 기준을 바꾸고 있으며, 최소 침습 기술과 외래 진료의 확대는 의료기기의 성능 요건을 재정의하고 있습니다. 국경 간 무역에 영향을 미치는 정책의 전환은 공급망 민첩성에 대한 필요성을 강화하고, 제조업체들이 조달처와 제조 거점을 재검토하도록 유도하고 있습니다.

자주 묻는 질문

  • 뼈핀 시장 규모는 어떻게 예측되나요?
  • 뼈핀의 임상적 중요성은 무엇인가요?
  • 뼈핀 시장에서 재료 혁신은 어떤 변화를 가져오고 있나요?
  • 2025년 미국의 관세 정책은 뼈핀 공급망에 어떤 영향을 미치나요?
  • 뼈핀 시장의 지역별 동향은 어떤가요?
  • 뼈핀 부문에서 경쟁 구도는 어떻게 형성되고 있나요?

목차

제1장 서문

제2장 조사 방법

제3장 주요 요약

제4장 시장 개요

제5장 시장 인사이트

제6장 미국 관세의 누적 영향(2025년)

제7장 AI의 누적 영향(2025년)

제8장 뼈핀 시장 : 제품 유형별

제9장 뼈핀 시장 : 재료별

제10장 뼈핀 시장 : 용도별

제11장 뼈핀 시장 : 최종 사용자별

제12장 뼈핀 시장 : 판매 채널별

제13장 뼈핀 시장 : 지역별

제14장 뼈핀 시장 : 그룹별

제15장 뼈핀 시장 : 국가별

제16장 미국의 뼈핀 시장

제17장 중국의 뼈핀 시장

제18장 경쟁 구도

AJY 26.04.16

The Bone Pins Market was valued at USD 187.39 million in 2025 and is projected to grow to USD 199.45 million in 2026, with a CAGR of 6.51%, reaching USD 291.56 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 187.39 million
Estimated Year [2026] USD 199.45 million
Forecast Year [2032] USD 291.56 million
CAGR (%) 6.51%

Comprehensive framing of bone pins' clinical importance, manufacturing evolution, and stakeholder priorities that underpin contemporary implant decision-making

Bone pins occupy a pivotal role in contemporary orthopedic and dental practice, acting as essential mechanical interfaces that restore anatomical continuity and enable functional recovery following a broad spectrum of musculoskeletal injuries. Clinicians select among a range of materials and designs to balance biomechanical strength, corrosion resistance, biocompatibility, and long-term patient outcomes. In tandem, manufacturers pursue material science advances and refined manufacturing techniques to reduce complications, improve integration, and facilitate minimally invasive approaches. This introduction situates bone pins within the larger ecosystem of implantable devices, highlighting the interplay among clinical requirements, regulatory expectations, and supply chain dynamics.

Recent years have seen an emphasis on patient-centric metrics such as implant removal rates, infection incidence, and post-operative mobility, which increasingly influence procurement and clinical decision-making. Consequently, product developers and health systems are testing novel polymeric and metallic solutions that provide either temporary support with predictable resorption profiles or durable fixation with minimal biological reactivity. Moreover, hospitals and ambulatory centers are adapting perioperative workflows and inventory strategies to support a broader array of pin types and sizes, recognizing that durable clinical outcomes stem from the combined quality of the device, surgical technique, and postoperative care protocols. This introductory context sets the stage for deeper analysis of transformative trends, trade policy impacts, segmentation intelligence, regional characteristics, and action-oriented recommendations that follow.

How material breakthroughs, minimally invasive techniques, and evolving procurement frameworks are reshaping product development and clinical adoption dynamics

The market landscape for bone pins is undergoing rapid transformation driven by intersecting technological, clinical, and operational shifts. Material innovation is at the forefront, with novel biodegradable polymers and magnesium-based alloys altering the treatment calculus for surgeons who prioritize reduced need for secondary removal procedures. Simultaneously, additive manufacturing and precision machining have enabled tighter tolerances, improved surface finishes, and complex geometries that enhance primary stability while reducing soft tissue irritation. These engineering advances directly influence implant performance and broaden the pool of cases in which certain pin types are clinically appropriate.

Beyond materials and manufacturing, clinical practice patterns are changing as minimally invasive methods and outpatient orthopedic care expand. External fixation and internal fixation techniques are being re-evaluated to optimize recovery timelines and lower perioperative costs, prompting clinicians to reassess preferred pin designs such as smooth versus threaded profiles. Parallel to clinical drivers, procurement models are evolving: hospitals and specialty centers increasingly leverage centralized purchasing and vendor rationalization to manage inventory complexity. Regulatory frameworks are also tightening around biocompatibility testing and post-market surveillance, compelling manufacturers to invest in higher levels of evidence and traceability. Cumulatively, these shifts are redefining product development roadmaps and market entry strategies for both established suppliers and new entrants.

The 2025 tariff environment forcing strategic sourcing, nearshoring, and inventory resilience strategies across the bone pins supply chain

Tariff policy shifts in the United States in 2025 introduced new considerations into supply chain planning and sourcing strategies for medical device companies, affecting the bone pins ecosystem in particular. Firms that had previously relied on cross-border manufacturing and component sourcing faced recalibrated cost structures and delivery lead times, encouraging nearshoring and diversification of supplier bases. This policy environment reinforced the importance of resilient logistics plans and inventory buffers to maintain consistent supply to hospitals, ambulatory centers, and orthopedic clinics.

In response, many manufacturers intensified efforts to localize critical manufacturing stages, invest in domestic finishing lines, and qualify alternative material suppliers to mitigate tariff-exposed inputs. Procurement teams at hospital purchasing departments evaluated total landed cost rather than unit price alone, giving greater weight to reliability, warranty, and service agreements. At the same time, distributors and direct sales organizations renegotiated commercial terms to accommodate shifting cost pass-throughs and to preserve access for smaller buyers. The net effect was an acceleration of strategic sourcing reviews and contract renegotiations that prioritized supply continuity and regulatory compliance over short-term cost savings, while also stimulating innovation in packaging, sterilization logistics, and vendor-managed inventory models.

Precise segmentation-driven insights that map material types, product forms, clinical applications, end-user settings, and sales channel implications for commercialization

A detailed segmentation lens clarifies where innovation and commercial focus are concentrated within the bone pins domain. When analyzed by material, product stakeholders are navigating choices among biodegradable, stainless steel, and titanium options; within biodegradable solutions there is a further distinction between metal and polymer approaches, where metal-based biodegradable solutions like magnesium alloy contrast with polymeric options such as polyglycolic acid and polylactic acid in terms of resorption kinetics and mechanical profile. These material distinctions shape clinical decision pathways by aligning patient needs-temporary support versus permanent fixation-with the implant's biological behavior.

Examining product type reveals distinct clinical preferences for smooth pins versus threaded pins, each offering trade-offs in ease of insertion, rotational stability, and removal characteristics. Application-specific dynamics span dental surgery, external fixation, internal fixation, and spinal surgery, with each clinical domain imposing unique mechanical and regulatory requirements that influence design optimization. End user segmentation underscores the importance of context: ambulatory centers, hospitals (both private and public), orthopedic clinics, and specialty centers exhibit divergent purchasing cycles, capital constraints, and clinical protocols, which downstream providers must anticipate. Lastly, sales channel strategy matters; manufacturers and suppliers deploy direct sales, third-party distributors, hospital purchasing departments, and online channels in different combinations to reach buyers effectively, tailoring service models and contract terms to match each channel's operational realities. Together, these segmentation dimensions provide a practical framework for prioritizing R&D, commercialization, and market access activities.

Regional market dynamics shaping clinical adoption, regulatory alignment, and distribution strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics exert a material influence on clinical practice patterns, regulatory expectations, and commercial strategies in the bone pins market. In the Americas, clinical adoption is influenced by a mix of sophisticated hospital systems and a growing network of ambulatory centers that prioritize throughput and predictable outcomes; this environment rewards devices that simplify perioperative workflows and demonstrate clear patient-centric benefits. Manufacturers targeting these markets often prioritize compliance with stringent regulatory standards and responsive commercial support structures to address hospital purchasing department requirements.

The Europe, Middle East & Africa region presents a heterogeneous landscape in which regulatory harmonization efforts coexist with varied procurement mechanisms; public hospitals and private providers can demonstrate markedly different procurement cycles and reimbursement environments. Consequently, suppliers must tailor evidence generation and pricing strategies to distinct national contexts. In the Asia-Pacific region, rapid capacity expansion in both clinical infrastructure and local manufacturing capabilities creates opportunities for cost-competitive innovation, yet also intensifies competition from domestic producers. Across all regions, effective market entry requires alignment of clinical evidence, distribution partnerships, and logistic capabilities to ensure safe, timely, and economically viable access to surgeons and care facilities.

Competitive landscape analysis revealing how material differentiation, clinical evidence, and channel evolution determine leadership and niche opportunities

Competitive dynamics in the bone pins space reflect a mix of established medical device manufacturers and specialized firms that focus on niche materials or clinical applications. Leading companies concentrate on developing differentiated materials, refining manufacturing precision, and expanding service offerings-such as sterile packaging innovations and clinician training programs-to reduce post-operative complications and shorten time to ambulation. Many commercial leaders also invest in evidence generation, including prospective clinical registries and post-market surveillance studies, to support both regulatory compliance and payer engagement.

At the same time, smaller innovators and start-ups are advancing disruptive concepts in bioresorbable metals and next-generation polymers, often partnering with academic clinical centers to validate safety and efficacy. Distribution and channel partners are also evolving: hospital purchasing departments increasingly demand integrated supply solutions, distributors focus on value-added services like just-in-time delivery and consignment models, and online channels are emerging for certain standardized pin types. The convergence of these competitive behaviors is driving consolidation in some segments and creating whitespace for focused companies that can align product performance with clearly articulated clinical and economic outcomes.

Actionable strategic priorities for manufacturers and suppliers to align innovation, local resilience, clinical partnerships, and diversified commercial models

Industry leaders should adopt a multi-pronged strategy that accelerates innovation while ensuring supply reliability and clinical relevance. First, prioritize modular R&D roadmaps that advance both biodegradable alloys and polymer platforms while preserving manufacturing flexibility to pivot between materials as clinical evidence and surgeon preferences evolve. Second, invest in local finishing and sterilization capabilities to reduce exposure to cross-border tariff shifts and to improve responsiveness to hospital purchasing cycles. Third, deepen collaboration with clinician stakeholders through structured training programs, real-world evidence generation, and registry participation to build trust and demonstrate long-term outcomes.

Additionally, refine commercial models to align with the purchasing realities of different end users: design bundled offerings and service-level agreements for hospitals, streamlined SKUs and support materials for ambulatory centers, and targeted educational content for orthopedic clinics. Expand distribution strategies by combining direct sales for strategic accounts with distributor partnerships and calibrated online availability for commoditized SKUs. Finally, embed post-market surveillance and patient-reported outcomes into product lifecycles to facilitate regulatory compliance and strengthen value conversations with payers and providers. Implementing these recommendations will sharpen competitive positioning and reduce operational vulnerability in an environment characterized by rapid clinical evolution and supply-chain complexity.

Transparent, triangulated research methodology combining clinical literature, regulatory review, and stakeholder interviews to validate insights and practical implications

This research applied a triangulated methodology combining systematic literature review, regulatory filings analysis, and primary stakeholder engagements to ensure robust and verifiable insights. Peer-reviewed clinical studies and device registries were examined to assess safety and performance trends across material classes and product types, while regulatory documents and standards were reviewed to map compliance trajectories. Supplier disclosures, patent filings, and manufacturing process descriptions were synthesized to identify technological inflection points and production constraints.

Primary research included interviews with orthopedic surgeons, procurement leads at hospitals and ambulatory centers, distributors, and medical device engineers to capture operational realities and adoption barriers. These qualitative inputs were cross-validated with secondary sources to ensure consistency and to surface divergent perspectives. Wherever applicable, sensitivity checks and scenario analyses were used to test assumptions related to supply-chain disruptions and policy changes. The methodology emphasized transparency, replicability, and a focus on clinically meaningful endpoints, enabling decision-makers to rely on the findings for strategic planning and operational adjustment.

Synthesis of clinical, technological, and operational drivers emphasizing the conditions for durable competitive advantage in the bone pins sector

In conclusion, bone pins remain a foundational element of orthopedic and dental care, yet the landscape is being reshaped by material innovation, shifting clinical pathways, and evolving procurement behaviors. Biodegradable materials and advanced alloys are changing the calculus around implant permanency and post-operative management, while minimally invasive techniques and ambulatory care expansion are redefining device performance requirements. Policy shifts affecting cross-border trade have reinforced the need for supply-chain agility, prompting manufacturers to rethink sourcing and manufacturing footprints.

Looking ahead, organizations that couple technical excellence with rigorous clinical evidence and adaptive commercial models will be best positioned to capture emerging opportunities. Collaboration across clinicians, regulatory bodies, and procurement organizations will be essential to translate material science advances into improved patient outcomes and operational efficiencies. Ultimately, strategic investments in local resilience, clinician engagement, and value-oriented sales approaches will determine which firms lead in delivering safer, more effective bone pin solutions to diverse care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bone Pins Market, by Product Type

  • 8.1. Smooth Pin
  • 8.2. Threaded Pin

9. Bone Pins Market, by Material

  • 9.1. Biodegradable
    • 9.1.1. Metal
    • 9.1.2. Polymer
      • 9.1.2.1. Polyglycolic Acid
      • 9.1.2.2. Polylactic Acid
  • 9.2. Stainless Steel
  • 9.3. Titanium

10. Bone Pins Market, by Application

  • 10.1. Dental Surgery
  • 10.2. External Fixation
  • 10.3. Internal Fixation
  • 10.4. Spinal Surgery

11. Bone Pins Market, by End User

  • 11.1. Ambulatory Centers
  • 11.2. Hospitals
    • 11.2.1. Private
    • 11.2.2. Public
  • 11.3. Orthopedic Clinics
  • 11.4. Specialty Centers

12. Bone Pins Market, by Sales Channel

  • 12.1. Direct Sales
  • 12.2. Distributors
  • 12.3. Hospital Purchasing Departments
  • 12.4. Online Channels

13. Bone Pins Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bone Pins Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bone Pins Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bone Pins Market

17. China Bone Pins Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Acumed by Colson Medical, LLC
  • 18.6. Arthrex, Inc.
  • 18.7. Assure Enterprises
  • 18.8. CONMED Corporation
  • 18.9. Gebr. Brasseler GmbH & Co. KG
  • 18.10. GerVetUSA
  • 18.11. GPC Medical Ltd.
  • 18.12. GWS Surgicals LLP.
  • 18.13. HAROLDMEDI LLC
  • 18.14. HEMC Ortho
  • 18.15. Innomed, Inc.
  • 18.16. Integra LifeSciences Holdings Corporation
  • 18.17. Johnson & Johnson
  • 18.18. Kaushik Orthopaedic Pvt. Ltd.
  • 18.19. Medline Industries, LP.
  • 18.20. Medtronic plc
  • 18.21. MicroPort Scientific Corporation
  • 18.22. Nebula Surgical Pvt. Ltd.
  • 18.23. Orthofix Medical Inc.
  • 18.24. reens Surgicals Pvt. Ltd.
  • 18.25. RTI Surgical Holdings, Inc.
  • 18.26. Shagun Cares Inc.
  • 18.27. Sharma Orthopedic (India) Private Limited
  • 18.28. Sky Surgicals
  • 18.29. Smit Medimed Pvt. Ltd.
  • 18.30. Smith & Nephew plc
  • 18.31. Stryker Corporation
  • 18.32. Surgical Holdings
  • 18.33. Zimmer Biomet Holdings, Inc.
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제